TSTickerStarGet alerts

bioAffinity Technologies Reports Q3 2026 Results

bioAffinity Technologies reported Q3 2026 revenue of $1.07 million, down 26% year-over-year from $1.45 million in Q3 2025, due primarily to decreased average reimbursement per CyPath Lung test. The company reported a net loss of $5.28 million compared to a net loss of $5.05 million in the prior-year quarter. Cash and cash equivalents were $2.55 million as of September 30, 2026, down from $6.45 million at December 31, 2025.

Share this story

Key takeaways

  • Revenue decreased 26% year-over-year to $1.07 million in Q3 2026 due to lower average reimbursement per CyPath Lung test

  • Net loss widened to $5.28 million from $5.05 million in Q3 2025, with operating loss increasing to $3.51 million from $2.29 million

  • CyPath Lung unit sales increased 100% year-to-date through Q3 2026 compared to the first nine months of 2025

  • Testing revenue for the first nine months of 2026 increased 79% to approximately $1.1 million compared to the same period in 2025

  • Operating expenses increased 23% year-over-year to $4.58 million, driven by additional sales and marketing personnel and clinical trial costs

  • The company expanded its government healthcare distribution network through an agreement with AvMEDICAL to serve VA and other government agencies

  • Cash position declined to $2.55 million as of September 30, 2026, with approximately $4.0 million raised in financing subsequent to quarter-end

Key metrics

Total RevenueQ3 2026
$1,070,280-26%
Net RevenueNine months ended September 30, 2026
$3,932,386-14%
Net LossQ3 2026
$5,277,023+5%
Net LossNine months ended September 30, 2026
$12,273,715+4%
Loss from OperationsQ3 2026
$3,510,672+53%
CyPath Lung Testing RevenueNine months ended September 30, 2026
~$1.1 million+79%
CyPath Lung Unit SalesNine months ended September 30, 2026 (vs. same period 2025)
+100%+100%
Cash and Cash EquivalentsSeptember 30, 2026
$2,550,034

Primary source

TickerStar generated this brief from an official company, investor-relations, earnings-call, or regulatory source. Review the primary material before making an investment decision.

Open SEC filing

Follow BIAF in real time

Get material earnings, filing, IR, and earnings-call alerts by email.

Create a free alert